（Ｒ‐）ＣＨＯＰ療法に伴う便秘の予防を目的とした酸化マグネシウムの投与開始時期に関する検討

Abstract

We investigated the optimum time for starting the administration of magnesium oxide for obtaining the best prevention of severe constipation due to (R-)CHOP therapy (combination therapy with cyclophosphamide,doxorubicin,vincristine (VCR),and prednisolone) with or without rituximab.Thirty-eight patients who received (R-)CHOP therapy at JA Mie Suzuka General Hospital were examined retrospectively.Use of a glycerin enema was adopted as a criterion for constipation as stated in Common Terminology Criteria for Adverse Events v 3.0 (JCOG/JSCO version).The median time for starting magnesium oxide was day 5 following administration of VCR in patients receiving glycerin enemas,which was significantly later than for patients not receiving glycerin enemas (day 1,p<0.01).In addition,the median duration of lack of bowel movement following administration of VCR in patients receiving glycerin enemas (2days) was significantly longer than that in the patients not receiving them (<1 day,p<0.01).Furthermore,patients who received magnesium oxide prior to or on the same day as VCR administration needed glycerin enemas significantly less frequently than patients who received magnesium oxide after VCR (p<0.05).Our results suggest that the use of magnesium oxide before (R-)CHOP therapy is beneficial in preventing the progression of constipation and should provide a useful reference for constipation care in patients receiving (R-)CHOP therapy.